Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma.

Abstract

Optic neuropathies such as glaucoma are characterized by retinal ganglion cell (RGC) degeneration and death. The sigma-1 receptor (S1R) is an attractive target for treating optic neuropathies as it is highly expressed in RGCs, and its absence causes retinal degeneration. Activation of the S1R exerts neuroprotective effects in models of retinal degeneration. Pridopidine is a highly selective and potent S1R agonist in clinical development. We show that pridopidine exerts neuroprotection of retinal ganglion cells in two different rat models of glaucoma. Pridopidine strongly binds melanin, which is highly expressed in the retina. This feature of pridopidine has implications to its ocular distribution, bioavailability, and effective dose. Mitochondria dysfunction is a key contributor to retinal ganglion cell degeneration. Pridopidine rescues mitochondrial function via activation of the S1R, providing support for the potential mechanism driving its neuroprotective effect in retinal ganglion cells.

• Authors: Michal Geva, Noga Gershoni-Emek, Luana Naia, Philip Ly, Sandra Mota, Ana Cristina Rego, Michael R Hayden, Leonard A Levin
• Journal: Scientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 21975 (11 09 2021) ISSN: 2045-2322 [Electronic] England
• PMID: 34753986 (Publication Type: Journal Article)
• Copyright: © 2021. The Author(s).

Chemical References

• Neuroprotective Agents
• Piperidines
• Reactive Oxygen Species
• Receptors, sigma
• pridopidine

Topics

• Animals
• Disease Models, Animal
• Dose-Response Relationship, Drug
• Glaucoma (metabolism, pathology, prevention & control)
• Mitochondria (drug effects)
• Neuroprotective Agents (administration & dosage, pharmacology)
• Piperidines (administration & dosage, pharmacology)
• Rats
• Reactive Oxygen Species (metabolism)
• Receptors, sigma (agonists)
• Retinal Ganglion Cells (drug effects, metabolism)
• Sigma-1 Receptor